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Oral Presentations 9TCD-BM1Tregs (4.5 105) compared to recipients of allogeneic
HCT only (p\ 0.05). We next examined the effects of pre-HCT
infusion of Tregs: Tregs (4 or 1.5  105) were transplanted 24 hr.
post-conditioning either 3 days pre-HCT or co-transplanted with
(day 0) donor TCD-BM. Although no difference was observed us-
ing higher Treg doses, pre-infusion - but not co-transplant of low
Treg doses was able to induce chimerism in these recipients. One
month post-HCT of TCD-BM alone, the frequency of circulating
host anti-donor tetramer1 (the immunodominant epitope H60)
CD81 cells in these recipients rejecting themarrow graft was clearly
greater compared to recipients of TCD-BM1Tregs both of which
engrafted (p\ 0.0008). However, the host anti-donor CD8 levels
were equivalent in recipients of TCD-BM alone and TCD-BM 1
Day 0 low doseTreg administration which failed to engraft. Nota-
bly, transplants using unmanipulated host Tregs failed to support
engraftment. These findings indicate that donor Tregs support chi-
merism via suppression of host anti-donor antigen-specific T cells.
Finally, the persistence of donor cells in circulation as well as in lym-
phoid tissues 3 months post-HCT indicated that long-term, stable
chimerism was established by this pre-HCT Treg regimen.
Together, our results demonstrate that donor Tregs promote
MHC-matched allogeneic marrow engraftment by suppressing
host anti-donor responses. Thus, the strategy of pre-HCTTreg in-
fusion is consistent with the notion that antigen-driven expansion of
donor anti-host reactive Treg cells can enhance hematopoietic en-
graftment. We are currently investigating host Treg expansion in
MHC-matched HCT recipients.AUTOLOGOUS TRANSPLANTS18
UTILITY OF CO-MORBIDITY ASSESSMENT IN PREDICTING TRANS-
PLANT-RELATED TOXICITY FOLLOWING AUTOLOGOUS HEMATOPOI-
ETIC TRANSPLANTATION FOR MULTIPLE MYELOMA
Labonte, L.1, Iqbal, T.2, Zaidi, M.A.1, McDiarmid, S.A.2,
Huebsch, L.B.2, Tay, J.2, Allan, D.S.1,2. 1Ottawa Health Research Pro-
gram, Ottawa, ON, Canada; 2University of Ottawa/The Ottawa Hospi-
tal, Ottawa, ON, Canada.
Background: Several randomized studies have demonstrated the
benefits and favorable toxicity following autologous hematopoietic
stem cell transplantation (AHSCT) for patients with multiple mye-
loma (MM)who are less than 55 yrs. Treatment related toxicity may
increase for older patients with co-morbidities and the benefits of
AHSCT become debatable. Decision tools for identifyingmyeloma
patients most suitable for AHSCT are needed to avoid the risk of
excess toxicity.Methods:Data regarding co-morbidities and toxic-
ity following transplant were extracted from the hospital records
and BMT database from 126 patients with MM undergoing
AHSCT between 1994 and 2006. All patients consented to the
use of medical information for research purposes. Co-morbidity
was assessed using the Charlson Co-morbidity Index (CCI), the
Haematopoietic Cell Transplantation Co-morbidity Index
(HCT-CI) and a modified Pretransplantation Assessment of Mor-
tality (mPAM). Transplant-related toxicity was assessed using
length of hospital stay (LOS) following the transplant, the total
number of organs having any toxicity according to the Seattle crite-
ria, cumulative toxicity using the scores in 8 organ systems, and non-
relapse mortality at 100 days. Results: Any co-morbidity using the
CCI (score. 0) was associated with prolonged LOS (OR 4.05, 1.76
– 9.29 for LOS greater than 18 days), more organ systems with any
toxicity (OR 2.27, 0.99 – 5.22 for at least one organ), and greater cu-
mulative organ toxicity (OR 2.2, 1.06 – 4.49 for total score $2).
Likewise, any co-morbidity using the HCT-CI (score . 0) was
also associated with longer LOS (OR 5.34, 2.24 – 12.75), increased
organ systemswith any toxicity (OR 2.5, 1.08 – 5.80) and cumulative
overall toxicity (OR 2.22, 1.08 – 4.55). A score of $24 using the
mPAM was associated with increased LOS (OR 3.03, 1.35 – 6.77)
but not with an increased number of organs with any toxicity or
with cumulative toxicity. None of the co-morbidity assessment
scales was associated with non-relapse mortality due to low inci-
dence of transplant-related death in this group (2 deaths or 1.6%).
Conclusion: Any co-morbidity identified using the CCI andHCT-CI was associated with greater toxicity following autologous
transplant for multiple myeloma. None of the scales was associated
with increasedmortality in this group. In discussingAHSCT for pa-
tients with myeloma, assessment of co-morbidities using the CCI or
HCT-CI may assist in determining the risk of toxicity.GRAFT PROCESSING19
PHARMACOLOGIC INHIBITION OF ALDEHYDE DEHYDROGENASE
(ALDH) CAUSES THE EXPANSION OF HEMATOPOIETIC STEM CELLS
(HSCs) WITH ENHANCED ENGRAFTMENT CAPACITY
Muramoto, G.G., Himburg, H., Meadows, S., Salter, A., Chao, N.J.,
Chute, J.P. Duke University, Durham, NC.
Delayed engraftment and graft failure are persistent obstacles
which limit the application of umbilical cord blood (CB) transplan-
tation in adults. We recently demonstrated that inhibition of
ALDH with diethylaminobenzaldehyde (DEAB) induced the ex-
pansion of human HSCs capable of repopulating NOD/SCID
mice (PNAS 2006 103:11707). In this study, we utilized syngeneic
CD45.1/CD45.2 mice to determine whether inhibition of ALDH
could accelerate the engraftment of transplantedHSCs in vivo. Cul-
ture of murine c-kit1sca-11lin-CD34- (34-KSL) cells with 100
mM DEAB coupled with thrombopoietin, SCF and Flt-3 ligand
(TSF) for 7 days resulted in a 22.6-fold expansion of total cells, com-
pared with 360.0-fold expansion with TSF alone (p5 0.001). How-
ever, DEAB-culture maintained a significantly higher percentage of
lin- (mean 97.1%) and KSL cells (mean 14.1%) at day 7 as com-
pared to TSF alone (42.6% and 4.7%, respectively; p\ 0.001 and
p5 0.03), indicating that inhibition of ALDH preferentially main-
tained more primitive progenitors in culture than TSF alone.
We then transplanted FACS-sorted donor CD45.11 BM
34-KSL cells or their progeny following culture with TSF alone
or TSF 1 DEAB at limiting doses into lethally irradiated
CD45.21 congenic recipients. At 4 weeks post-transplantat,
DEAB-cultured progeny showed significantly accelerated engraft-
ment in recipient mice, as compared to day 0 34-KSL cells or their
progeny following culture with TSF alone. Using Poisson statistical
analysis, the repopulating cell frequency was found to be 1 in 48.4
for the DEAB-cultured progeny (95% confidence interval: 27.3 –
86.0) as compared to 1 in 99.6; CI: 50.4 – 197.0) within the TSF-
cultured progeny. Unmanipulated BM 34-KSL cells had not yet
shown significant levels of hematopoietic engraftment at week 4
(1 in 1319.4; CI 187.2 – 9298.8). DEAB-cultured progeny also dem-
onstrated significantly higher B2201 and Thy 1.21 lymphoid con-
tribution, as compared to day 0 BM 34-KSL cells (p\ 0.001 and
p\0.001), and significantly higher level ofMac-11/Gr-11myeloid
reconstitution (p \ 0.001), compared with the progeny of TSF
alone. These data demonstrate that pharmacologic inhibition of
ALDH facilitates the differential expansion of hematopoietic pro-
genitors with enhanced early engraftment capacity. This strategy
can be particularly useful to expand human CB grafts to overcome
the delays in engraftment which currently limit this otherwise
attractive source of HSCs for adult transplantation.20
HIGHER CD341 CELL DOSES ARE ASSOCIATED WITH DECREASED RE-
LAPSE RATES FOLLOWING UNRELATED DONOR ALLOGENEIC PERIPH-
ERAL BLOOD STEM CELL TRANSPLANTATION WITH TRENDS TO
IMPROVED DISEASE-FREE SURVIVAL
Nakamura, R.1, Auayporn, N.1, Smith, D.D.2, Palmer, J.2, Sun, J.Y.1,
Schriber, J.3, Pullarkat, V.1, Parker, P.1, Rodriguez, R.1, Stein, A.1,
Rosenthal, J.1, Wang, S.4, Karanas, C.1, Senitzer, D.1, Forman, S.J.1.
1City of Hope National Medical Center, Duarte, CA; 2City of Hope Na-
tional Medical Center, Duarte, CA; 3City of Hope/Samaritan Hemato-
poietic Cell Transplantation Program, Phoenix, AZ; 4City of Hope
National Medical Center, Duarte, CA.
10 Oral PresentationsPeripheral blood stem cells (PBSC) have been increasingly used
in the matched unrelated donor (MUD) transplant setting, but
the impact of CD341 cell dose on outcomes in this setting have
not been well characterized. We analyzed a consecutive case-series
of 181 patients who underwentMUD-PBSC transplantation at City
of Hope from August 2000 to December 2004. Eighty-three pa-
tients were conditioned with a full-intensity regimen (TBI-Cy:
46, TBI-VP16: 28, Bu-Cy: 9) and 98 received a reduced-intensity
regimen (Flu-Mel: 97, Flu-Bu: 1). The two-year overall survival
(OS), disease-free survival (DFS), relapse, and 100-day transplant-
related mortality (TRM) probabilities were 52%64%, 47%64%,
29%64%, and 156 3% respectively. There was a highly significant
correlation betweenCD341 cell dose infused and absolute lympho-
cyte count on day 30 post-transplant (r 5 0.378, p\ 0.0001). By
univariate analysis, a CD341 cell dose $4.2  106/kg (above the
lowest quartile: p25) was associated with significantly lower relapse
risk (HR5 0.67; p5 0.013), with a trend toward improved disease-
free survival (HR 5 0.84; p 5 0.12) but not overall survival (HR 5
0.91; p5 0.46). There was no significant association between higher
CD341 cell dose and TRM or acute/chronic GVHD. By multivar-
iate analysis, cellular composition of the PBSC grafts remained sig-
nificant in influencing transplant outcomes (Table 1). Further
subset analysis of low risk group (n 5 35) versus high-risk disease
(n5 146) showed that the CD341 dose$ p25 was significantly as-
sociated with reduced relapse in high-risk disease (p 5 0.015),
whereas the p-value was not significant in low-risk disease (p 5
0.5). Among 18 patients with an iKIRL mismatch in the GVH di-
rection, the log-rank p-value for comparing\ p25 of CD341 cell
dose versus those who received higher doses was p\ 0.0001 with
respect to time to relapse. This is in contrast with p5 0.041 among
the others. We also performed a stratified analysis in patients lack-
ing iKIRL (n 5 56) versus not (n 5 125). When stratified by
CD341 cell dose, time-to-relapse was not significant among the pa-
tients who did not lack iKIRL but was significant in patients lacking
iKIRL (p 5 0.0030). In summary, we demonstrate that the higher
CD341 cell dose reduces relapse in MUD-PBSCT, in particular,
for high-risk diseases. The data also suggest that the protective ef-
fect of higher CD341 cell dose may be linked to an NK cell-medi-
ated GVL effect.Table 1.
HR p-valuesOS
10/10 HLA match
(baseline) vs. others2.23 (95%CI: 1.46–3.43) 0.0002Lymphocyte dose in
the graft (continuous)0.20 (95%CI: 0.05–0.64) 0.005MNC dose in the
graft: p25 (baseline)
vs. others1.34 (95%CI: 1.01–1.82) 0.04DFS
10/10 HLA match
(baseline) vs. others1.91 (95%CI: 1.28–2.87) 0.001Lymphocyte dose in
the graft (continuous)0.35 (95%CI: 0.14–0.81) 0.01Good risk disease
(baseline) vs. others1.73 (95%CI: 1.01–3.17) 0.04Relapse
CD341 quartile: p25
(baseline) vs. others0.64 (95%CI: 0.47–0.88) 0.01Recipient age
(continuous)1.02 (95%CI: 1.00–1.05) 0.02TRM
10/10 HLA match
(baseline) vs. others2.46 (95%CI: 1.44–4.30) 0.001Full-intensity
(baseline) vs.
reduced-intensity
conditioning1.76 (95%CI: 1.03–3.10) 0.04MNC: mononuclear cell.21
PREPARATION OF HIGHLY PURIFIED REGULATORY T CELLS FOR CLIN-
ICAL APPLICATIONS
Sheehan, K.1, Armstrong, R.1, Tudisco, C.1, Hou, J.-Z.2, Negrin, R.1.
1Stanford University Medical Center, Stanford, CA; 2University of
Pittsburgh Medical Center, Pittsburgh, PA.
Naturally occurring regulatory T cells (Treg) may limit or pre-
vent the immune mediated morbidity associated with allogeneic
transplants. The administration of Treg along with specified doses
of conventional T cells (Tcon) has been proposed as an alternative
to current T cell reduction strategies. This approach may provide
patients with immune protection and graft-versus-tumor activity
during post-transplant immune reconstitution while minimizing
the risk of severe graft-versus-host responses when the donor and
recipient are mismatched.
In order to establish the optimal dose of Treg to be administered
with Tcon, highly purified Treg are required. Isolation of Tregs for
clinical application is complicated by the lack of an exclusive surface
marker suitable for selection and the relatively rare representation
(\1%) of the cells in peripheral blood. Treg are characterized by
surface expression of CD4, CD25, CTLA-4, and GITR among
other markers and by intracellular expression of the transcriptional
factor FoxP3.
We conducted a feasibility study of a cell selection strategy that
combines immunomagnetic enrichment of CD251 cells with high
flow cytometric speed cell sorting of CD41CD25brightCD127dim
cells. System operations took into consideration selection effi-
ciency, effect on cell viability and functionality as well as the
risk of contamination both from external sources and product
cross-contamination. Using this approach, we have obtained cells
that are .95% FoxP31 by intracellular staining and showing ti-
tratable suppression in MLR assays. Recovery of the target cell
population on the Influx cell sorter was .90% at 20,000 events
per second and without detectable microbial contamination. In ad-
dition, more than 100  106 FoxP31 Tregs were routinely ob-
tained from individual G-CSF mobilized donor apheresis
collections.GVH/GVL22
DISCOVERY OF LEUKEMIA ASSOCIATED MINOR HISTOCOMPATIBILITY
ANTIGENS USING CD81 T CELL CLONES ISOLATED BY PRIMARY IN VI-
TRO STIMULATION OF NAI¨VE T CELLS
Bleakley, M.1, Nishida, T.1, Otterud, B.2, Riddell, S.1. 1Fred Hutchinson
Cancer Research Center, Seattle, WA; 2University of Utah, Salt Lake
City, UT.
Allogeneic hematopoietic stem cell transplantation (HCT) is cu-
rative for many patients with leukemia in part due to a graft versus
leukemia (GVL) effect mediated by donor T cells specific for recip-
ient minor histocompatibility antigens (miH) on leukemic cells.
Unfortunately, the GVL effect fails to completely eradicate leu-
kemia in some patients, and additional strategies for preventing
and treating post HCT relapse are required. Immunotherapy tar-
geting miH selectively expressed on hematopoietic cells, includ-
ing leukemia, could be used to augment the GVL effect
without inducing GVHD but too few human miH have been mo-
lecularly characterized for this approach to be broadly applied.
The identification of additional leukemia associated miH is essen-
tial. We developed a new strategy that employs primary in vitro
stimulation of donor naı¨ve CD81 T cells (TN) with recipient
APC in microcultures, allowing generation of a broad repertoire
of miH specific CTL for gene discovery. Using this approach,
.100 miH specific CD81 CTL lines were derived from 19
HLA identical sibling recipient-donor pairs and further charac-
terized using a panel of target cells from unrelated individuals
to determine the HLA restricting allele and population frequency
of the miH. CTL directed against multiple distinct miH were
